The union of Vector Laboratories and Absolute Biotech, facilitated by Thompson Street Capital Partners, is a strategic move that strengthens both companies’ positions in the industry. This merger enhances their combined capabilities as manufacturers of critical components and expands their joint commercial presence in key markets.
Vector Laboratories, known for its reagents and components for life sciences development, is a valuable partner for biopharma companies. With this merger, Vector expands its global reach and provides faster delivery of products and services.
Absolute Biotech, a manufacturer and supplier of antibody reagents, aims to make recombinant antibodies more accessible. They offer a comprehensive antibody portfolio to support various antibody-related processes.
The merged entity possesses manufacturing capabilities for small and large-scale projects, allowing them to support customers throughout the drug and diagnostic development processes.
The merger streamlines the process for biopharma customers by providing integrated solutions that reduce development time and resource commitments. Suppliers with expertise in antibody-drug conjugates are vital to the success of pharma and biotech clients, and this merger strengthens their offering in this area.
Integrating Absolute Biotech’s validated antibodies with Vector’s detection reagents creates a comprehensive suite of solutions for assay developers in translational and pre-clinical research.
This merger aligns with Thompson Street Capital Partners’ vision of building a comprehensive platform that supports the life sciences industry from early-stage research to clinical trials.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
